A 63-year-old man with long-standing type 2 diabetes, prior myocardial infarction, eGFR 65 mL/min/1.73 m², and HbA1c 7.8% despite metformin is reviewed. According to Diabetes Canada pharmacologic guidance, which additional agent most appropriately addresses both glycaemic control and cardiovascular risk reduction?